Leukemia Clinical Trials

Showing 6141-6160 of 8,366 trials

Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian

NCT01219777

The purpose of this study is to determine the maximum tolerated dose (MTD) of intravenous weekly paclitaxel given with intravenous carboplatin and bevacizumab in patients with epithelial ovarian, primary peritoneal, or fallopian tube carcinoma that are to receive neoadjuvant chemotherapy (prior to surgical cytoreduction). Patients will then undergo surgery which will allow an objective measure of response to the above regimen as well as assessment of surgical outcomes.

Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer

Ritu Salani9 participantsStarted Sep 2010

Columbus, Ohio, United States

UNKNOWN

Does CMV Induced Changes in NK Lymphocyte Biology Influence the Effectiveness of Antibody Therapy Used to Treat B Cell Lymphoproliferative Diseases?

NCT03417414

This is an observational cohort study of patients with a new diagnosis of B cell Chronic Lymphocytic Leukemia or B cell Non-Hodgkin's Lymphoma who will receive an anti-CD20 monoclonal antibody treatment during the induction phase of their treatment. Throughout the study, patients will have four blood draws at specified time points throughout the study. The initial blood draw will be analysed test patients for Cytomegalovirus and conduct a g-NK cell analysis. The final three blood draws will be conducted to analyse the g-NK cells at specified time points. The objectives of this study are to: 1) characterize the frequency of CMV (+) and g-NK (+) individuals in the B-NHL and B-CLL populations, 2) Determine changes in circulating g-NK cells during and after anti-CD20 monoclonal antibody containing remission induction chemotherapy and 3) Evaluate whether the presence of g-NK cells improve the outcome of anti-CD20 monoclonal antibody containing remission induction treatment of patients with B-NHL or B-CLL.

B Cell Lymphocytic LeukemiaB Cell Non-Hodgkin's Lymphoma

Ottawa Hospital Research Institute160 participantsStarted Mar 2018

Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian

Does CMV Induced Changes in NK Lymphocyte Biology Influence the Effectiveness of Antibody Therapy Used to Treat B Cell Lymphoproliferative Diseases?

Related Searches

Comparison of Liposomal Doxorubicin and Daunorubicin-containing VDCLD Regimen in the Treatment of Adult ALL Patients

A Study of DCC-2701 in Participants With Advanced Solid Tumors

Transformation Into Small Cell Lung Cancer : a Mode of Resistance to Treatment

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma

Prandial Insulin Dosing in Hospitalized Patients

Detecting Radiation-Induced Cardiac Toxicity After Non-Small Cell Lung Cancer Radiotherapy

Renal Artery Stenting in Patients With Documented Resistant Hypertension and Atherosclerotic Renal Artery Stenosis (ANDORRA)

Evaluation of the Comprehensive Primary Care Plus (CPC+) Model

Safety Study of ADV-specific T-cells in Paediatric Patients Post Allo-HSCT

Clinical and Biological Efficacy of Hazelnut Oral Immunotherapy

Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer

Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia

Total Marrow and Lymphoid Irradiation and Chemotherapy for Myelodysplastic Syndrome or Acute Leukemia

Aspiring to Awesome- Patient Preference Privacy Selections in EMR

Icotinib Combined With Dihydroaremisinin (DHA) Therapy in Patients With Advanced NSCLC

TR(ACE) Assay Clinical Specimen Study

Predictors of Positive Food Challenge